Article Text

PDF
In vivo imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy
  1. A Cagnin1,
  2. S D Taylor-Robinson2,
  3. D M Forton2,
  4. R B Banati3
  1. 1Department of Neurosciences, University of Padova, Padova, Italy, IRCCS-Ospedale San Camillo, Venezia, Italy, and MRC Cyclotron Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital Campus, London, UK
  2. 2Robert Steiner MR Unit, Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital Campus, London, UK, and Division of Medicine A, Imperial College London, Hammersmith Hospital Campus, London, UK
  3. 3MRC Cyclotron Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital Campus, London, UK, Department of Neuropathology, Imperial College London, Charing Cross Hospital Campus, London, UK, and School of Medical Radiation Sciences and Ramaciotti Centre for Brain Imaging, Brain-Mind Research Institute, University of Sydney, Lidcombe, New South Wales, Australia
  1. Correspondence to:
    Professor R B Banati
    School of Medical Radiation Sciences and Ramaciotti Centre for Brain Imaging, University of Sydney, East St PO Box 170, Lidcombe, NSW 1825, Australia; r.banati{at}fhs.usyd.edu.au

Abstract

Background and aim: One proposed mechanism whereby hepatic encephalopathy (HE) leads to loss of brain function is dysregulated synthesis of neurosteroids. Mitochondrial synthesis of neurosteroids is regulated by “peripheral benzodiazepine binding sites” (PBBS). Expressed in the brain by activated glial cells, PBBS can be measured in vivo by the specific ligand [11C](R)-PK11195 and positron emission tomography (PET). Recently, it has been suggested that PBBS expressing glial cells may play a role in the general inflammatory responses seen in HE. Therefore, we measured PBBS in vivo in the brains of patients with minimal HE using [11C](R)-PK11195 PET.

Methods: Five patients with minimal HE and biopsy proven cirrhosis of differing aetiology were assessed with a neuropsychometric battery. Regional expression of PBBS in the brain was detected by [11C](R)-PK11195 PET.

Results: All patients showed brain regions with increased [11C](R)-PK11195 binding. Significant increases in glial [11C](R)-PK11195 binding were found bilaterally in the pallidum, right putamen, and right dorsolateral prefrontal region. The patient with the most severe cognitive impairment had the highest increases in regional [11C](R)-PK11195 binding.

Conclusion: HE is associated with increased cerebral binding of [11C](R)-PK11195 in vivo, reflecting increased expression of PBBS by glial cells. This supports earlier experimental evidence in rodent models of liver failure, suggesting that an altered glial cell state, as evidenced by the increase in cerebral PBBS, might be causally related to impaired brain functioning in HE.

  • HE, hepatic encephalopathy
  • PBBS, peripheral benzodiazepine binding sites
  • PET, positron emission tomography
  • GABA, gamma-aminobutyric acid
  • HCV, hepatitis C virus
  • NCT, number connection tests
  • EEG, electroencephalogram
  • MRI, magnetic resonance imaging
  • MRS, magnetic resonance spectroscopy
  • BP, binding potential
  • hepatic encephalopathy
  • glia
  • peripheral benzodiazepine binding sites
  • PK11195
  • positron emission tomography

Statistics from Altmetric.com

Footnotes

  • Published online first 12 October 2005

  • Conflict of interest: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Alastair Watson